文献速递肿瘤 PET/CT

纳武利尤单抗治疗中肿瘤免疫反应的动态变化:18F-FDG PET/CT显示

Dynamic Adaptation of Tumor Immune Response With Nivolumab Demonstrated by 18F-FDG PET/CT.
PubMed 文献 · Clin Nucl Med · 2018-01-01

一例61岁女性肺腺癌患者一线治疗失败后接受纳武利尤单抗免疫治疗,FDG-PET/CT显示开始治疗后7周胸部淋巴结仅轻度残留活性、其余病灶完全缓解,15周出现腋窝及锁骨上淋巴结增大且FDG摄取增高,20周时上述淋巴结病变明显改善。该病例提示晚期出现的疾病进展仍可对持续免疫治疗有反应,作者假设其机制是免疫治疗增强的免疫系统与肿瘤之间动态博弈。

要点

  • 纳武利尤单抗治疗7周后FDG-PET/CT示胸部淋巴结轻度残留活性、其余病灶完全缓解
  • 治疗15周出现腋窝及锁骨上淋巴结增大且FDG摄取增高
  • 治疗20周FDG-PET/CT示腋窝及锁骨上淋巴结病变明显改善

核心结论

  • 该病例表明,晚期出现的疾病进展仍可对持续免疫治疗有反应,作者假设其原因是免疫治疗增强的免疫系统与肿瘤之间动态博弈中的动态适应。

研究设计与样本

  • 个案报道:一例61岁女性肺腺癌患者,一线治疗失败后接受纳武利尤单抗免疫治疗,并在治疗前及治疗7周、15周、20周行FDG-PET/CT评估。

主要发现

  • 免疫治疗前FDG-PET/CT示胸部淋巴结、肝、肾上腺及骨骼转移。
  • 开始纳武利尤单抗7周后FDG-PET/CT示胸部淋巴结轻度残留活性,其余病灶完全缓解。
  • 15周后出现腋窝淋巴结增大且FDG摄取增高,锁骨上淋巴结病变加重。
  • 20周后FDG-PET/CT示腋窝及锁骨上淋巴结病变明显改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 61-year-old woman with lung adenocarcinoma failed first-line treatment and was placed on immunotherapy with nivolumab. FDG-PET/CT before immunotherapy showed metastases to thoracic nodes, liver, adrenal gland, and skeleton. Seven weeks after starting nivolumab, FDG-PET/CT showed mild residual activity in thoracic nodes and otherwise complete response. After 15 weeks, enlarged and FDG-avid axillary lymphadenopathy and worsening supraclavicular lymphadenopathy developed. After 20 weeks, FDG-PET/CT demonstrated marked improvement of axillary and supraclavicular lymphadenopathy. This case demonstrates that later progression of disease can still respond to continuing immunotherapy, hypothetically because of dynamic adaptations in the tug-of-war between the immunotherapy-augmented immune system and tumor.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Eshghi N, Lundeen TF, Kuo PH, et al. Dynamic Adaptation of Tumor Immune Response With Nivolumab Demonstrated by 18F-FDG PET/CT. Clin Nucl Med. 2018. PMID: 29261621. doi:10.1097/RLU.0000000000001934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。